Showing results (111-120 of 267) with videos related to

Sort By:
Pageof 27
Gynakologisch-Geburtshilfliche Rundschau|April 7, 2009
Placental growth factor: a predictive marker for preeclampsia?Markus Schmidt, Canan Dogan, Cahit Birdir, et al.
Oncology Research|April 10, 2010
The CYP1A1 Ile462Val polymorphism and platinum resistance of epithelial ovarian neoplasmsMartin Heubner, Pauline Wimberger, Kathrin Riemann, et al.
The Journal of Maternal-Fetal & Neonatal Medicine : the Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians|April 29, 2016
Impact of maternal serum levels of Visfatin, AFP, PAPP-A, sFlt-1 and PlGF at 11-13 weeks gestation on small for gestational age birthsCahit Birdir, Janina Fryze, Stefanie Frölich, et al.
Molecular Human Reproduction|August 13, 2009
Progestins inhibit expression of MMPs and of angiogenic factors in human ectopic endometrial lesions in a mouse modelVerena Mönckedieck, Carolin Sannecke, Bettina Husen, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|April 2, 2017
Follistatin during pregnancy and its potential role as an ovarian suppressing agentAngela Köninger, Börge Schmidt, Daniela Damaske, et al.
Archives of Gynecology and Obstetrics|June 28, 2015
Single nucleotide polymorphisms of the EpCAM-coding gene TACSTD1 in patients with ovarian cancer and their potential translational aspectsMartin Heubner, Pauline Wimberger, Sabine Kasimir-Bauer, et al.
Breast Cancer Research : BCR|February 13, 2016
Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapySabine Kasimir-Bauer, Ann-Kathrin Bittner, Lisa König, et al.
Reproductive Biomedicine Online|August 28, 2018
Trends in anti-Müllerian hormone concentrations across different stages of pregnancy in women with polycystic ovary syndromeAngela Köninger, Antje Kampmeier, Boerge Schmidt, et al.
Oncotarget|April 19, 2017
EMT-like circulating tumor cells in ovarian cancer patients are enriched by platinum-based chemotherapyIssam Chebouti, Sabine Kasimir-Bauer, Paul Buderath, et al.
Frontiers in Oncology|November 5, 2019
Soluble Programmed Death Receptor Ligands sPD-L1 and sPD-L2 as Liquid Biopsy Markers for Prognosis and Platinum Response in Epithelial Ovarian CancerPaul Buderath, Esther Schwich, Christina Jensen, et al.
Pageof 27